Praegnant Breast Cancer: Early/Advanced/Metastatic
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Among patients with breast cancer the subgroup of patients with metastases are considered the group of patients with the worst prognosis. Not only regard-ing therapy decisions but also with regard to quality assured healthcare and health economics this entity of patients remains a challenge. Recently, novel advances in breast cancer therapy aim at the targeted therapy of tumor entities and identification of patients, for whom the greatest therapy benefit, and the least side effects are expected. However molecular assessment of the patient and the tumor in the metastatic situation is not performed on a routine basis and in many cases tumor character-istics from the primary tumor are considered reliable enough to make therapy decisions for the metastatic patients. Although molecular reassessment of tu-mor characteristics from tumor material of the metastasis is recommended in national guidelines, only a minority of patients is biopsied, because of the inva-siveness of the procedure, even though biopsy related complications are reported to be rare. With modern analytic methods from blood based biomaterial there seems to be an opportunity to correlate blood based tumor assessments with actual charac-teristics of the tumor. These include expression analysis, tumor mutation analy-sis, tumor gene copy number aberrations and others. One of the main aims of the PRAEGNANT study is therefore to establish an infrastructure for the compre-hensive analysis of tumor and metastatic molecular characteristics of the patient and the tumor. Furthermore, health care related outcomes as well as health economics provide novel approaches for integration of patients in study conduct and health care awareness and are study aims of the PRAEGNANT study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Dorosłe osoby (18 lat lub więcej)
- •Zdiagnozowany rak piersi bez przerzutów do odległych organów
- •Diagnoza postawiona nie więcej niż 91 dni przed włączeniem do badania
- •Chęć i możliwość podpisania świadomej zgody
- •Zaawansowany lub miejscowo nieoperacyjny rak piersi z przerzutami potwierdzonymi obrazowaniem
✗ Disqualifies
- •Brak podpisanej świadomej zgody
- •Poważne problemy zdrowotne uniemożliwiające udział w badaniu, oceniane przez lekarza
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- January 30, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (61)
Klinikum Sindelfingen-Böblingen gGmbH
Böblingen, Germany
Klinik für Frauenheilkunde, Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
NCT Heidelberg
Heidelberg, Germany
ViDia Christliche Kliniken Karlsruhe
Karlsruhe, Germany
Praxisklinik am Rosengarten
Mannheim, Germany
medius Klinik Nürtingen
Nürtingen, Germany
Universitätsfrauenklinik Tübingen
Tübingen, Germany
Universitätsfrauenklinik Ulm
Ulm, Germany
Gesundheitszentrum St. Marien GmbH
Amberg, Germany
Anregiomed gKK Klinikum Ansbach Brustzentrum Westmittelfranken
Ansbach, Germany
Hämatologische-onkologische Praxis
Augsburg, Germany
Klinikum Augsburg
Augsburg, Germany
Sozialstiftung Bamberg Klinikum am Bruderwald
Bamberg, Germany
Klinikum Bayreuth
Bayreuth, Germany
DONAUISAR Klinikum
Deggendorf, Germany
Onkologisches Zentrum Donauwörth
Donauwörth, Germany
Rottal-Inn-Kliniken GmbH
Eggenfelden, Germany
Universitätsfrauenklinik Erlangen
Erlangen, Germany
Klinikum Fürth
Fürth, Germany
MVZ am Klinikum Aschaffenburg - Zweigpraxis für Hämatologie und Onkologie
Hösbach, Germany
Onkologie Elisenhof, München
München, Germany
Klinikum der Universität München Frauenklinik
München, Germany
Frauenklinik und Poliklinik der Technischen Universität München
München, Germany
Caritas-Krankenhaus St. Josef
Regensburg, Germany
Universitätsklinikum Würzburg
Würzburg, Germany
Praxis für Frauenheilkunde und Geburtshilfe
Fürstenwalde, Germany
Ruppiner Kliniken GmbH, Hochschulklinikum der Med. Hochschule Brandenburg
Neuruppin, Germany
Immanuel Klinik und Poliklinik Rüdersdorf GmbH
Rüdersdorf, Germany
Universitätsklinikum Hamburg-Eppendorf
Hamburg, Germany
Onkologie Lerchenfeld
Hamburg, Germany
Klinikum Darmstadt Frauenklinik
Darmstadt, Germany
Centrum für Hämatologie und Onkologie Bethanien
Frankfurt am Main, Germany
Klinikum Kassel GmbH
Kassel, Germany
Gemeinschaftspraxis für Hämatologie und Onkologie
Langen, Germany
Lahn-Dill-Kliniken GmbH Klinikum Wetzlar
Wetzlar, Germany
Niels-Stensen-Kliniken
Georgsmarienhütte, Germany
Onkologische Schwerpunktpraxis Leer-Emden
Leer, Germany
g.SUND Gynäkologie Kompetenzzentrum Stralsund
Stralsund, Germany
Uniklinik RWTH Aachen
Aachen, Germany
Gynäkologie und Geburtshilfe im medizinischen Zentrum Bonn
Bonn, Germany
Marienhospital
Bottrop, Germany
Universitätsfrauenklinik Düsseldorf
Düsseldorf, Germany
Kliniken Essen-Mitte
Essen, Germany
—
Herne, Germany
Institut für Versorgungsforschung in der Onkologie GbR
Koblenz, Germany
St. Vincenz-Krankenhaus GmbH
Paderborn, Germany
Praxis Onkologie und Hämatologie
Recklinghausen, Germany
Gesellschaft für Medizinische Studien Würselen
Würselen, Germany
Schwerpunktpraxis für Hämatologie und Onkologie
Kaiserslautern, Germany
Institut für Versorgungsforschung
Mayen, Germany
Klinikum Chemnitz gGmbH
Chemnitz, Germany
Universitätsklinik Dresden
Dresden, Germany
Universitäres Krebszentrum Leipzig
Leipzig, Germany
Kreiskrankenhaus Torgau
Torgau, Germany
Universitätsklinikum Halle (Saale)
Halle, Germany
Klinik für Gynäkologie und Geburtshilfe
Kiel, Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, Germany
Charité
Berlin, Germany
MediOnko-Institut GbR
Berlin, Germany
Klinik für Gynäkologie und Geburtshilfe, Helios Kliniken
Berlin, Germany
medius KLINIKEN gGmbH, medius KLINIK Ostfildern-Ruit
Ostfildern, Germany
Trial contact
Erik Belleville, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.